Multi-stakeholder consensus on a target product profile for an HIV cure
Sharon R. Lewin(The Royal Melbourne Hospital), Steven G. Deeks(University of California, San Francisco), Cathy Bansbach(Bill & Melinda Gates Foundation), Karine Dubé(University of California System), Mark Dybul(Center for Global Health), Devi SenGupta(Gilead Sciences (United States)), Izukanji Sikazwe(Centre for Infectious Disease Research in Zambia), Mitchell Warren, Thumbi Ndung’u(Ragon Institute of MGH, MIT and Harvard), James F. Rooney(Gilead Sciences (United States)), John C. Pottage(ViiV Healthcare (United Kingdom)), Gary J. Nabel(National Institutes of Health), David H. Brown Ripin(Clinton Health Access Initiative), Joseph M. McCune(Gladstone Institutes), Timothy Attoye(University of Washington), Rowena Johnston(American Foundation for AIDS Research), Moses Supercharger Nsubuga, Rosanne Lamplough(International AIDS Society), Adam Jiang(McKinsey & Company (United States)), Brian Doehle(Bill & Melinda Gates Foundation)
Cited by 79
Related Papers
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Systemic Effects of Inflammation on Health during Chronic HIV Infection
|Immunity|2013|835
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
|Blood|2004|787
Defective proviruses rapidly accumulate during acute HIV-1 infection
|Nature Medicine|2016|774